Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Hepatitis B is a liver infection that affects almost ... later someone might cite in a paper when they come up with a cure for some disease. Never in a million years did I expect to lead a project ...

To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Phase III study results demonstrate that tenofovir is superior to adefovir in treating HBV infection. Tenofovir was approved by the FDA in August 2008 for the treatment of patients with hepatitis ...

Access to vaccines and treatment is also more limited in some parts of Africa and Asia, where rates of infection are higher. Building a New Platform to Study Hepatitis B Digging into the mystery ...